About

The present report serves to better understand how therapeutics, both Paxlovid and Molnupiravir, have been used and distributed to treat COVID-19. Data come from 11 health systems (Allina Health, CentraCare, Children’s Hospitals and Clinics of Minnesota, Essentia Health, M Health Fairview, University of Minnesota, HealthPartners, Hennepin Healthcare, Mayo Clinic and Mayo Clinic Health System, and North Memorial Health, and Sanford Health) and includes people who resided in Minnesota at the time of treatment or received health care in Minnesota. We estimate that MNEHRC represents around 90 percent of healthcare in the state of Minnesota. While health systems are responsible for a large number of COVID-19 PCR (polymerase chain reaction) tests, many tests happen outside of health systems. COVID-19 tests included in this study represent a minority of all COVID-19 cases in Minnesota 2021-2023 – the exact proportion is not known. Because tests included in this study were administered by health care systems, positive tests may include more severe cases of COVID-19 than those that were never seen at a health system.

Data

The data in this report show the total number of therapeutic prescriptions and therapeutic prescriptions following a positive test for COVID-19. Therapeutic prescriptions in this report are limited to nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio), referred to as Paxlovid and Molnupiravir respectively in this report. Results are shown for overall and by race/ethnicity, age, sex, SVI, and rural/urban geography. A therapeutic presciption was determined to follow a positive COVID-19 PCR test if it occurred within 2 weeks following the administration of the test. Disparities analyses in sections 3 and 4 are limited to people ages 50+ in order to focus on people who are most likely to be considered for a therapeutic medication. The Minnesota Department of Health recognizes ages 50 and older as a risk factor for severe illness resulting from COVID-19, independent of underlying chronic medical conditions. Data are current as of 5/6/2024.

Dynamic HTML Report

Graphs in this HTML report are dynamic. Click on the colored lines in the legend to include or remove items from the graph. Hover over lines in the graph to see values for an item in a particular month.

Total Counts

Total Paxlovid prescriptions

246,358

Total Molnupiravir prescriptions

26,511

Total combined COVID-19 therapeutics

272,869

Total combined COVID-19 therapeutics prescriptions that followed a positive COVID-19 PCR test

40,103

Section 1: COVID-19 therapeutic prescriptions

Total therapeutic prescriptions

COVID-19 therapeutic prescriptions per positive COVID-19 PCR test

Total therapeutic prescriptions over time

Section 2: COVID-19 therapeutic prescriptions by demographics

Section 3: COVID-19 therapeutic prescriptions by PCR status

Therapeutic prescriptions by PCR testing status and age

Therapeutic prescriptions in patients aged 50+ by PCR testing status and sex

Therapeutic prescriptions in patients aged 50+ by PCR testing status and race/ethnicity

Therapeutic prescriptions in patients aged 50+ by PCR testing status and Social Vunerability Index (SVI)

Therapeutic prescriptions in patients aged 50+ by PCR testing status and rural/urban geography

Section 4: COVID-19 therapeutic prescriptions following a positive PCR test

Positive COVID-19 PCR tests by therapeutic prescriptions by age

Positive COVID-19 PCR tests by therapeutic prescriptions by age, over time

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by sex

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by sex, over time

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by race/ethnicity

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by race/ethnicity, over time

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by SVI

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by SVI, over time

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by rural/urban geography

Positive COVID-19 PCR tests by therapeutic prescriptions in patients aged 50+ by rural/urban geography, over time